Current scenario of drug development for leishmaniasis

by Croft SL, Seifert K, Yardley V. Indian J Med Res, March 2006,123(3):399-410. Review.

Summary: As part of research to identify better treatments for VL and cutaneous leishmaniasis (CL), alternative and potentially cheaper formulations of amphotericin B, alklyphosphocholines other than miltefosine and improved formulations of paromomycin for CL have been identified. The process for discovery and development of new antileishmanials would also benefit from improved models, for example, transfected parasites, and non invasive methods of measuring parasite load in rodent models of infection.

Click here to download the full article [PDF]